TY - JOUR
T1 - Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma
T2 - a multi-institutional study
AU - Abufaraj, Mohammad
AU - Moschini, Marco
AU - Soria, Francesco
AU - Gust, Kilian
AU - Özsoy, Mehmet
AU - Mathieu, Romain
AU - Rouprêt, Morgan
AU - Margulis, Vitaly
AU - Karam, Jose A.
AU - Wood, Christopher G.
AU - Briganti, Alberto
AU - Bensalah, Karim
AU - Haitel, Andrea
AU - Shariat, Shahrokh F.
N1 - Funding Information:
Open access funding is provided by Medical University of Vienna. Marco Moschini is supported by the EUSP Scholarship—European Association of Urology.
Publisher Copyright:
© 2016, The Author(s).
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Purpose: To assess the role of N-cadherin as prognostic biomarker in patients with upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients. Patients and methods: Immunohistochemistry was used to evaluate the status of N-cadherin expression in 678 patients with unilateral sporadic UTUC treated with radical nephroureterectomy. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. The Kaplan–Meier method was used to estimate recurrence-free survival, overall survival and cancer-specific survival. Disease recurrence, overall mortality and cancer-specific mortality probabilities were tested in Cox regression models. Results: Expression of N-cadherin was observed in 292 (43.1%) of patients, and it was associated with advanced tumour stage (p < 0.04), lymph node metastases (p = 0.04) and sessile architecture (p < 0.02). Within a median follow-up of 37.5 months (IQR 20–66), 171 patients (25.2%) experienced disease recurrence and 150 (22.1%) died from UTUC. In univariable analyses, N-cadherin expression was significantly associated with higher probability of recurrence (p = 0.01), but not overall (p = 0.9) or cancer-specific mortality (p = 0.06). When adjusted for the effects of all available confounders, N-cadherin was not associated with any of the survival outcomes. Conclusion: N-cadherin is expressed in approximately 2/5 of UTUs. It is associated with adverse pathologic factors but not with survival outcomes. Its clinical value remains limited.
AB - Purpose: To assess the role of N-cadherin as prognostic biomarker in patients with upper tract urothelial carcinoma (UTUC) in a large multi-institutional cohort of patients. Patients and methods: Immunohistochemistry was used to evaluate the status of N-cadherin expression in 678 patients with unilateral sporadic UTUC treated with radical nephroureterectomy. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. The Kaplan–Meier method was used to estimate recurrence-free survival, overall survival and cancer-specific survival. Disease recurrence, overall mortality and cancer-specific mortality probabilities were tested in Cox regression models. Results: Expression of N-cadherin was observed in 292 (43.1%) of patients, and it was associated with advanced tumour stage (p < 0.04), lymph node metastases (p = 0.04) and sessile architecture (p < 0.02). Within a median follow-up of 37.5 months (IQR 20–66), 171 patients (25.2%) experienced disease recurrence and 150 (22.1%) died from UTUC. In univariable analyses, N-cadherin expression was significantly associated with higher probability of recurrence (p = 0.01), but not overall (p = 0.9) or cancer-specific mortality (p = 0.06). When adjusted for the effects of all available confounders, N-cadherin was not associated with any of the survival outcomes. Conclusion: N-cadherin is expressed in approximately 2/5 of UTUs. It is associated with adverse pathologic factors but not with survival outcomes. Its clinical value remains limited.
KW - N-Cadherin
KW - Prediction
KW - Survival
KW - UTUC prognosis
KW - Upper tract urothelial carcinoma
KW - Urothelial carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84994438771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994438771&partnerID=8YFLogxK
U2 - 10.1007/s00345-016-1968-2
DO - 10.1007/s00345-016-1968-2
M3 - Article
C2 - 27830374
AN - SCOPUS:84994438771
SN - 0724-4983
VL - 35
SP - 1073
EP - 1080
JO - World journal of urology
JF - World journal of urology
IS - 7
ER -